Kathryn Stein

Biography

Kathryn Stein is an immunologist with over 30 years of experience in biotechnology as a senior manager at the FDA and as an executive in industry. She is an expert in the field of polysaccharide-protein conjugate vaccines and monoclonal antibodies. During her 22 years at the FDA, the last 10 as the first Director of the Division of Monoclonal Antibodies, Dr. Stein was a leader in developing policies to regulate polysaccharide-protein conjugate vaccines, monoclonal antibodies and other recombinant DNA-derived products. She was lead or co-author on all of the guidance documents published by the FDA with respect to monoclonal antibodies and a co-author of the FDA guidance on comparability. Dr. Stein was one of the approving officials for the Haemophilus influenza type b (Hib) vaccines for routine use in infants. She was a member of the review committee of the first approved monoclonal antibody, OKT3™, and one of the approving officials for the subsequent 15 monoclonal antibodies approved through the first half of 2002, including abciximab, rituximab, palivizumab, trastuzumab, infliximab, and alemtuzumab. Dr. Stein received numerous awards for her review and policy work at the FDA. She was the 2014 recipient of the John and Samuel Bard Award in Medicine and Science from Bard College, Annandale-on-Hudson, NY. In 2002, Dr. Stein left the FDA to join MacroGenics where she was responsible for establishing the Product Development and Regulatory Affairs, Project Management, Quality and Manufacturing departments. She served as Senior Vice President, Product Development and Regulatory Affairs until 2016. Under Dr. Stein’s leadership during her 14 year tenure, MacroGenics brought eight products into the clinic, seven of them newly developed by MacroGenics and one in-licensed as a phase 2/3 asset. Dr. Stein received a BA in chemistry from Bard College and a PhD in microbiology and immunology from the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Prior to joining the FDA, she was a post-doctoral Fellow at Harvard with Dr. Harvey Cantor and at NIH with Dr. William Paul. At FDA she was a Staff Fellow, Senior Investigator, and the first Director of the Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, CBER, FDA. She maintained a research laboratory for her entire 22 year career at FDA and was a leading investigator in polysaccharide-protein conjugate vaccines. She has over 60 peer-reviewed 

Research Interest

 biotechnology